Early induction of GAD65-reactive th2 response in type 1 diabetic children treated with alum-formulated GAD65

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 7, 2010, Pages 559-568

  Axelsson, Stina ^a   Hjorth, Maria ^a   Åkerman, Linda ^a   Ludvigsson, Johnny ^a   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cytokines; GAD65; Immunotherapy; T helper cells; Type 1 diabetes

Indexed keywords

DIAMYD; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 5; INTERLEUKIN 6; PHYTOHEMAGGLUTININ; PLACEBO; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TYROSINE PHOSPHATASE LIKE PROTEIN 1A 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CRYOPRESERVATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TH2 CELL;

ADOLESCENT; ALUM COMPOUNDS; AUTOANTIBODIES; CHILD; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOLOGIC FACTORS; INSULIN; INTERFERON-GAMMA; INTERLEUKINS; MONOCYTES; MULTICENTER STUDIES AS TOPIC; PROTEIN TYROSINE PHOSPHATASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651376427     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1126     Document Type: Article

References (40)

1. Atkinson MA, Maclaren NK. The pathogenesis of insulindependent diabetes mellitus. N Engl J Med 1994; 331(21): 1428-1436.
2. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314(21): 1360-1368.
3. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318(11): 663-670.
4. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54(6): 1763-1769.
5. Schloot NC, Meierhoff G, Lengyel C, et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007; 23(4): 276-285.
6. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of betacell function. N Engl J Med 2009; 361(22): 2143-2152.
7. Ludvigsson J. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity. Diabetologia 2009; 52(1): 75-76.
8. Tisch R, McDevitt H. Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity? Proc Natl Acad Sci U S A 1994; 91(2): 437-438.
9. Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunol Res 2008; 41(3): 175-187.
10. Kaufman D, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366(6450): 15-17.
11. Muir A, Peck A, Clare-Salzler M, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest1995; 95: 628-634.
12. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366(6450): 72-75.
13. Skyler J, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial - type 1. Diabetes Care 2005; 28: 1068-1076.
14. Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34(4): 408-415.
15. Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab Res Rev 2009; 25(4): 316-320.
16. Baekkeskov S, Aanstoot HJ, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347: 151-156.
17. Baekkeskov S, Kanaani J, Jaume JC, Kash S. Does GAD have a unique role in triggering IDDM? J Autoimmun 2000; 15(3): 279-286.
18. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man - macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 1991; 165(2): 97-103.
19. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Comp 2005; 19(4): 238-246.
20. Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359(18): 1909-1920.
21. Axelsson S, Faresjo M, Hedman M, et al. Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children. Cryobiology 2008; 57(3): 201-208.
22. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.Mixedmeal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31(10): 1966-1971.
23. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30(5): 636-645.
24. Tian J, Lu Y, Hanssen L, Dang H, Kaufman DL. Memory and effector T cells modulate subsequently primed immune responses to unrelated antigens. Cell Immunol 2003; 224(2): 74-85.
25. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3(2): 123-132.
26. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47(6): 894-899.
27. Tian J, Atkinson MA, Clare-Salzler M, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996; 183(4): 1561-1567.
28. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997; 186(12): 2039-2043.
29. Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 2006; 27(4): 183-187.
30. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8(4): 247-258.
31. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13(7): 843-850.
32. Lindenstrom T, Agger EM, Korsholm KS, et al.Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009; 182(12): 8047-8055.
33. Chen WY, Bluestone J, Herold K. Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol 2005; 24: 287-305.
34. Tian J, Clare-Salzler M, Herschenfeld A, et al.Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996; 2(12): 1348-1353.
35. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest 2003; 112(9): 1437-1443.
36. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37(1): 129-138.
37. Nowell P., Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. Cancer Res 1960; 20: 462-466.
38. Pfleger C, Meierhoff G, Kolb H, Schloot NC. Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. J Autoimmun 2010; 34(2): 127-135.
39. Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunol Res 2008; 42(1-3): 246-258.
40. Brewer JM,Conacher M,Hunter CA,Mohrs M,Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J Immunol 1999; 163(12): 6448-6454.